Welcome to DOAC
DOAC is sponsored by MCORRP as part of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). We invite your comments!
DOAC News
DOAC Dataform and DOSE Protocol Updated 12/02/2025
Submitted by admin on Thu, 2025-12-04 16:00WATCH Baseline patients will now be linked to the DOAC registry...
Submitted by admin on Mon, 2025-11-24 21:23WATCH Baseline patients will now be linked to the DOAC registry and entered into the database only if they meet the specific eligibility criteria.
DOAC Dataform and DOSE Protocol Updated 09/24/2025
Submitted by admin on Tue, 2025-10-07 14:24DOAC Dataform and Dictionary Updated 09/12/2025
Submitted by admin on Fri, 2025-09-12 13:11DOAC Dataform Updated 08/20/2024
Submitted by admin on Thu, 2024-08-22 17:23The data form document has been updated. We have added specific questions regarding hematuria adverse events in the follow-up form. Download it here.
DOSE Protocol updates posted 08/02/2024
Submitted by admin on Wed, 2024-08-07 17:04DOSE Protocol updates posted 02/16/2024
Submitted by admin on Mon, 2024-02-19 13:11The document was revised, for dabigatran (all Indications) and rivaroxaban (all Indications except CAD & PAD) to add the following statement: “Consider alternative anticoagulation in patients who develop significant acute renal failure”
DOSE Protocol updates posted 01/27/2024
Submitted by admin on Mon, 2024-01-29 11:10Page 3 of the document has been revised, for all DOACs, with the following “Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS)”.
DOSE Protocol updates posted 01/08/2024
Submitted by shensky on Mon, 2024-01-08 18:01DOSE protocol document was revised on 01/08/2024 - includes minor typo corrections.
